The advances in dealing with the safety of medicated drugs in pregnancy.
The advances in dealing with the safety of medicated drugs in pregnancy.
复制标题
处理妊娠期药物安全性的进展。
DOI：
10.35772/ghm.2020.01120
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
A. Yamatani
中科院分区：
文献类型：
--
作者：
A. Murashima;N. Yakuwa;Sachi Koinuma;Chiaki Uno;C. Takai;Izumi Fujioka;Mikako Goto;Naoki Ito;Omi Watanabe;A. Yamatani
日本妊娠期药物信息研究所（JDIIP）成立的目的是向担心妊娠期使用药物的妇女提供药物安全性信息，并通过基于咨询案例的流行病学研究提供证据。自成立以来，JDIIP通过促进怀孕期间正确使用药物，为母亲和儿童的健康做出了许多贡献。一个由47个都道府县的核心医院组成的网络在为生活在日本各地的妇女提供信息方面发挥着重要作用。由于我们要分析的药物暴露病例通常很少，因此有必要建立国内外畸形学信息服务网络，以提供高质量的证据。JDIIP一直通过使用“怀孕”和“药物”等关键词为药剂师和医生的教育以及各个医学会临床实践指南的制定做出贡献。今后的问题包括为寻求协商的人创造一个容易进入的环境，建立一个便于建立安全基础的机制，并致力于本组织的持续发展。
The Japan Drug Information Institute in Pregnancy (JDIIP) was established with the aims of providing information on drug safety to women who are worried about drug use during pregnancy and creating evidence through epidemiological studies based on counseling cases. Since being established, JDIIP has made many contributions to the wellness of mothers and children by promoting the proper use of drugs during pregnancy. A network consisting of Core hospitals in 47 prefectures plays an important role in providing information for women living anywhere in Japan. Because cases of exposure to drugs whose safety we want to analyze are usually rare, networks of domestic and foreign teratology information services are necessary in order to produce high-quality evidence. JDIIP has been contributing to the education of pharmacists and doctors and to the creation of clinical practice guidelines in various medical societies by using keywords such as "pregnancy" and "medication". Future issues include creating an environment that is easily accessible for those seeking consultation, building a mechanism that makes it easy to create a basis for safety, and aiming for the continuing development of the organization.